… in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) … In preclinical studies, dual
blockade of the EGFR and VEGF … : rationale and clinical applications for non-small-cell lung …

… Briefly, RELAY was a global, double-blind, placebo-… studies because study designs and
patient populations differ. In … safety reasons but in line with contemporary clinical trials in this …

… The RELAY study was a global, double-blind, placebo-… +ERL in patients with untreated
metastatic NSCLC and sensitizing … of patients with untreated EGFR mutation-positive stage IV …

… decisions to be made on a more rational basis. … -TKI treatment, subgroup analyses of
several landmark studies in EGFRm … Briefly, RELAY is a global, double-blind, placebo-controlled, …

… such as ramucirumab is a rational treatment strategy in EGFR-mutant NSCLC. Indeed, clinical
studies have … In REVEL, a randomized, double-blind Phase 3 trial, patients with previously …

Full article: Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib
versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung …

… of patients with epidermal growth factor receptor (EGFR)-… treatment observed in RELAY,
NEJ026, and other studies for … an independent review committee identified for this purpose and …

… placebo plus erlotinib in untreated EGFR-mutated metastatic … In the Asian subset of FLAURA,
a phase 3 double-blind study … of EGFR mutation-positive non-small cell lung cancer treated …

… , metastatic, EGFR-mutated, non–small-cell lung cancer (… reported, 36 RELAY is a randomized,
double-blind, Placebo-… an independent review committee identified for this purpose and …

… a double-blind, placebo-controlled phase III trial … RELAY subgroup analyses by EGFR
ex19del and ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung …